PTI 428

Drug Profile

PTI 428

Alternative Names: PTI-428

Latest Information Update: 30 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Proteostasis Therapeutics
  • Class Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cystic fibrosis

Highest Development Phases

  • Phase II Cystic fibrosis

Most Recent Events

  • 01 Jul 2018 Phase-II clinical trials in Cystic fibrosis (Adjunctive treatment) in USA (PO) (NCT03591094)
  • 08 May 2018 Proteostasis Therapeutics plans a phase III global clinical development program for Cystic fibrosis
  • 17 Apr 2018 Proteostasis Therapeutics plans a phase II trial of PTI 428 and tezacaftor/ivacaftor for Cystic fibrosis in the third quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top